iNFixion Bioscience Revenue and Competitors

The mission of iNFixion Bioscience is to develop drug therapies to treat and prevent the progression of all symptoms associated with Neurofibromatosis Type 1 (NF1), a rare genetic disorder impacting approximately 2.5M people worldwide. iNFixion’s unique approach to NF1 is to correct a key underlying genetic ‘mechanism of action’, namely the lack of functional Neurofibromin protein, by enhancing the affected person’s natural ability to both produce and maintain healthy Neurofibromin protein. By correcting this root cause mechanism, we believe that a fundamental and preventive impact on disease symptoms, and disease progression, will be achieved.